Author: KCCure

ASCO-GU 2019 Patient Perspective on CARMENA

19-02 Survey CARMENA ASCO GU KCCure

Kidney Cancer Patient Conference of North Carolina

Want to learn about the latest research in kidney cancer from world renowned experts? Interested in connecting with other patients and caregivers? Register today for this all day event on March 2nd in Chapel Hill, North Carolina. Full agenda is available here.  

New Localized Kidney Cancer Support Group

Have you been diagnosed with localized kidney cancer? KCCure has a new support community just for you. The KCCure 1-2-3 group is a support community for those managing a diagnosis of stage 1, stage 2 or stage 3 kidney cancer. Two thirds of patients will be diagnosed with localized kidney cancer – in other words, renal cell carcinoma in the kidney that has not spread into other organs. For almost a...

KCCure Announces Kidney Cancer Research Award of $100,000 to UNC Lineberger

WASHINGTON – The Kidney Cancer Research Alliance (KCCure) announced today that $100,000 has been awarded to Dr. Qing Zhang and Dr. Xianming Tan at the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill for their kidney cancer research proposal: TBK1 Serves as a Novel Therapeutic Target in Kidney Cancer with VHL Loss. “We are honored to receive this award from KCCur...

Voice of Kidney Cancer – Words from Forrest

Forrest is a stage 3 kidney cancer survivor.  He recently shared these thoughts in our clear cell kidney cancer patient community.  His words not only showcase how many patients feel on a daily basis – they also explain why we believe that connecting with other patients and caregivers is such a crucial part of survivorship for kidney cancer patients. Thank you Forrest for inspiring others! W...

KCCure joins over 300 advocacy organizations urging Congress to protect Medicare part B

KCCure has joined with 339 other advocacy organizations urging Congress to halt implementation of a new pricing scheme that could negatively impact kidney cancer patients covered by Medicare. The “International Pricing Index” model, proposed by the Centers for Medicare & Medicaid Services (CMS) would affect 50 percent of physicians and hospitals serving Medicare Part B beneficiarie...

Voice of Kidney Cancer – Amanda’s Story

Amanda Handcock shares the story of her dad’s brave fight with kidney cancer. Today, Amanda is an active advocate for other kidney cancer patients.  Thank you Amanda for sharing your story. Your dad is still inspiring others through your amazing voice. I can only hope he knew he was my hero. The man who I would compare all other men in my life. My father, Gary Wilfred Handcock, was a force t...

Treatment for Metastatic Kidney Cancer Edges Toward Approval

AVEO Oncology announced today that the Phase 3 TIVO-3 Trial of Tivozanib in metastatic kidney cancer has met its primary endpoint.

ESMO18 – Kidney Cancer Updates

KCCure reports live from #ESMO18 on kidney cancer updates and what we learned from the experts.

Lawing to Present on Rare Kidney Cancer at AACR Conference

Michael B. Lawing, Director of Outreach, KCCure has been selected to participate in the Scientist <-> Survivor Program at the 11th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved Nov. 2-5, 2018 in New Orleans, LA. The conference will address all levels of basic, population, clinical, and transdisciplinary research related ...

Voice of Kidney Cancer – Michael Robson

Today, the combination of Yervoy and Opdivo is approved in the U.S., Canada and Australia for treatment of first line metastatic kidney cancer, thanks in part to pioneers like kidney cancer patient Michael Robson who bravely participated in clinical trials. Most recently, Dr. Jim Allison was awarded the Nobel Prize in Medicine for his discovery of the mechanism that led to the development of these...

Letter to Kidney Cancer Journal and Response – Regarding Checkpoint Inhibitors in Non-Clear Cell RCC

Attached is a letter to the editor of the Kidney Cancer Journal and editorial response regarding the use of checkpoint inhibitors in non-clear cell RCC. We’re grateful to the editors of the journal for graciously providing this update for patients with rare types of kidney cancer. KCJ letter

  • 1
  • 2
  • 8

Lost Password


Subscribe for updates!